Cargando…
Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection?
Despite tremendous progress in modern-day stroke therapy, ischemic stroke remains a disease associated with a high socioeconomic burden in industrialized countries. In light of demographic change, these health care costs are expected to increase even further. The current causal therapeutic treatment...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140731/ https://www.ncbi.nlm.nih.gov/pubmed/35628192 http://dx.doi.org/10.3390/ijms23105381 |
_version_ | 1784715169828438016 |
---|---|
author | Haupt, Matteo Gerner, Stefan T. Bähr, Mathias Doeppner, Thorsten R. |
author_facet | Haupt, Matteo Gerner, Stefan T. Bähr, Mathias Doeppner, Thorsten R. |
author_sort | Haupt, Matteo |
collection | PubMed |
description | Despite tremendous progress in modern-day stroke therapy, ischemic stroke remains a disease associated with a high socioeconomic burden in industrialized countries. In light of demographic change, these health care costs are expected to increase even further. The current causal therapeutic treatment paradigms focus on successful thrombolysis or thrombectomy, but only a fraction of patients qualify for these recanalization therapies because of therapeutic time window restrictions or contraindications. Hence, adjuvant therapeutic concepts such as neuroprotection are urgently needed. A bench-to-bedside transfer of neuroprotective approaches under stroke conditions, however, has not been established after more than twenty years of research, albeit a great many data have demonstrated several neuroprotective drugs to be effective in preclinical stroke settings. Prominent examples of substances supported by extensive preclinical evidence but which failed clinical trials are tirilazad and disodium 2,4-sulphophenyl-N-tert-butylnitrone (NXY-059). The NXY-059 trial, for instance, was retrospectively shown to have a seriously weak study design, a trial of insufficient quality and a poor statistical analysis, although it initially met the recommendations of the STAIR committee. In light of currently ongoing novel neuroprotective stroke trials, such as ESCAPE-NA, and to avoid the mistakes made in the past, an improvement in study quality in the field of stroke neuroprotection is urgently needed. In the present review, animal models closely reflecting the “typical” stroke patient, occlusion techniques and the appropriate choice of time windows are discussed. In this context, the STAIR recommendations could provide a useful orientation. Taking all of this into account, a new dawn for neuroprotection might be possible. |
format | Online Article Text |
id | pubmed-9140731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91407312022-05-28 Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? Haupt, Matteo Gerner, Stefan T. Bähr, Mathias Doeppner, Thorsten R. Int J Mol Sci Review Despite tremendous progress in modern-day stroke therapy, ischemic stroke remains a disease associated with a high socioeconomic burden in industrialized countries. In light of demographic change, these health care costs are expected to increase even further. The current causal therapeutic treatment paradigms focus on successful thrombolysis or thrombectomy, but only a fraction of patients qualify for these recanalization therapies because of therapeutic time window restrictions or contraindications. Hence, adjuvant therapeutic concepts such as neuroprotection are urgently needed. A bench-to-bedside transfer of neuroprotective approaches under stroke conditions, however, has not been established after more than twenty years of research, albeit a great many data have demonstrated several neuroprotective drugs to be effective in preclinical stroke settings. Prominent examples of substances supported by extensive preclinical evidence but which failed clinical trials are tirilazad and disodium 2,4-sulphophenyl-N-tert-butylnitrone (NXY-059). The NXY-059 trial, for instance, was retrospectively shown to have a seriously weak study design, a trial of insufficient quality and a poor statistical analysis, although it initially met the recommendations of the STAIR committee. In light of currently ongoing novel neuroprotective stroke trials, such as ESCAPE-NA, and to avoid the mistakes made in the past, an improvement in study quality in the field of stroke neuroprotection is urgently needed. In the present review, animal models closely reflecting the “typical” stroke patient, occlusion techniques and the appropriate choice of time windows are discussed. In this context, the STAIR recommendations could provide a useful orientation. Taking all of this into account, a new dawn for neuroprotection might be possible. MDPI 2022-05-11 /pmc/articles/PMC9140731/ /pubmed/35628192 http://dx.doi.org/10.3390/ijms23105381 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Haupt, Matteo Gerner, Stefan T. Bähr, Mathias Doeppner, Thorsten R. Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title | Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title_full | Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title_fullStr | Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title_full_unstemmed | Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title_short | Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection? |
title_sort | quest for quality in translational stroke research—a new dawn for neuroprotection? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140731/ https://www.ncbi.nlm.nih.gov/pubmed/35628192 http://dx.doi.org/10.3390/ijms23105381 |
work_keys_str_mv | AT hauptmatteo questforqualityintranslationalstrokeresearchanewdawnforneuroprotection AT gernerstefant questforqualityintranslationalstrokeresearchanewdawnforneuroprotection AT bahrmathias questforqualityintranslationalstrokeresearchanewdawnforneuroprotection AT doeppnerthorstenr questforqualityintranslationalstrokeresearchanewdawnforneuroprotection |